HIMS · CIK 0001773751
What Hims & Hers Health, Inc. told the SEC could break it.
Hims & Hers' disclosures revolve around dependence on third parties it doesn't fully control. Certain offerings — including its weight-loss and compounded GLP-1 products — are primarily fulfilled by a single supplier, so if that supplier stopped filling orders, fulfillment would slow significantly until new suppliers are onboarded or in-house manufacturing scales. More broadly, its model leans on affiliated medical groups for consultations, partner pharmacies for fulfillment, and manufacturing suppliers for products and ingredients. And those offerings sit under FDA (and UK/EU/Canada) approval requirements, with its compounded products depending on meeting Section 503A/503B exemption rules — a pointed exposure amid FDA scrutiny of compounded GLP-1s.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Sole-source dependency
- single supplier for certain offerings (incl. weight-loss / compounded GLP-1)high
Certain Hims & Hers offerings — including weight-loss/compounded GLP-1 products — are primarily fulfilled by one supplier; if that supplier stopped fulfilling orders, fulfillment would be significantly slowed until new suppliers are onboarded or internal manufacturing scales.
“Certain of our weight loss offerings are primarily fulfilled by one supplier. If this supplier stops fulfilling purchase orders, it could significantly slow our ability to fulfill these orders until new suppliers are identified and fully onboarded and/or our internal manufacturing capabilities are expanded, which could adversely impact our results of operations”
SEC filing →As of 2026
Other disclosures
- dependence on Affiliated Medical Groups, Partner Pharmacies & Manufacturing Suppliersmedium
Hims & Hers depends on third-party Affiliated Medical Groups (providers) for consultations, Partner Pharmacies for fulfillment/distribution, and Manufacturing Suppliers for products/ingredients (including compounded GLP-1s) — over which it has limited control.
“we depend on our relationships with Manufacturing Suppliers to supply and/or manufacture certain of our products or product ingredients, including compounded GLP-1s, to the Pharmacies.”
SEC filing →As of 2026
Regulatory & policy
- FDA drug/device approval & compounding (Section 503A/503B)low
Hims & Hers' products require FDA (and UK/EU/Canada) approval/authorization and its compounded offerings depend on meeting Section 503A/503B FDCA exemption requirements — a material exposure given FDA scrutiny of compounded GLP-1s.
“The prescription drug and medical device products available through our platform require approval or authorization by the FDA (and equivalent regulatory authorities in the United Kingdom, the European Union, and Canada) and are subject to the limitations placed by the FDA (or equivalent regulatory authorities in the United Kingdom, the European Union, and Canada) on the approved or authorized uses in the product prescr”
SEC filing →As of 2026
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch